GlassScriptPhysician profile
Ravi P Gada
NPI 1063527588
$9,678.04
in general payments reported to CMS, 2019-2025
13 companies · $400 in 2025
The $400 reported for 2025 was more than what 84% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,940 · 2020: $507 · 2021: $595 · 2022: $462 · 2023: $342 · 2024: $432 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $6,473.26 | 2019-2022 | |
| Coopersurgical, INC. | $1,248.18 | 2019-2025 | Stripper, Origio Sequential Fert |
| Organon LLC | $742.19 | 2021-2025 | Ganirelix Acetate, Follistim Aq, Pregnyl |
| Emd Serono, INC. | $621.81 | 2019-2025 | |
| Abbvie INC. | $196.72 | 2019-2021 | |
| Covidien LP | $150.58 | 2019 | |
| Hologic Sales and Service, LLC | $121.80 | 2019-2023 | Myosure Tissue Removal Device |
| Galen US INC | $29.88 | 2019-2021 | |
| Minerva Surgical, INC | $23.09 | 2021 | |
| Meditrina | $22.12 | 2025 | |
| Astellas Pharma US INC | $21.13 | 2023 | Veozah |
| Merck Sharp & Dohme LLC | $16.94 | 2020 | |
| Neuronetics, INC. | $10.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Gada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.